1. Home
  2. ANTA vs CGEN Comparison

ANTA vs CGEN Comparison

Compare ANTA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANTA

Antalpha Platform Holding Company Ordinary Shares

HOLD

Current Price

$9.00

Market Cap

227.5M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.16

Market Cap

220.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTA
CGEN
Founded
2022
1993
Country
Singapore
Israel
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
227.5M
220.7M
IPO Year
2025
2000

Fundamental Metrics

Financial Performance
Metric
ANTA
CGEN
Price
$9.00
$2.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$17.50
$4.00
AVG Volume (30 Days)
4.5K
591.3K
Earning Date
11-10-2025
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
669.18
N/A
EPS
0.47
N/A
Revenue
$65,033,103.00
$6,903,000.00
Revenue This Year
$69.27
N/A
Revenue Next Year
$64.32
$164.92
P/E Ratio
$19.24
N/A
Revenue Growth
63.28
N/A
52 Week Low
$8.50
$1.13
52 Week High
$27.72
$2.66

Technical Indicators

Market Signals
Indicator
ANTA
CGEN
Relative Strength Index (RSI) 43.30 66.02
Support Level $9.00 $2.04
Resistance Level $9.99 $2.38
Average True Range (ATR) 0.31 0.15
MACD -0.01 0.05
Stochastic Oscillator 22.59 73.64

Price Performance

Historical Comparison
ANTA
CGEN

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: